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Background: Seizures are one of the most important neurologic complications of human immuno-deficiency virus
(HIV)-negative cryptococcal meningitis. A better understanding of the risk associated factors can help predict those
who will require treatment.
Methods: This 22-year retrospective study enrolled 180 patients. Prognostic variables independently associated with
seizures or fatality were analyzed using stepwise logistic regression.
Results: Twenty-eight patients with HIV-negative cryptococcal meningitis had seizures, including 13 with early seizures
and 15 with late seizures. The mean time interval from HIV-negative cryptococcal meningitis to first seizure in the early
and late seizure groups were 1.5 and 51.4 days, respectively. Nine out of the 28 cases (32%) occurred within 24 hours
of presentation. The overall mortality rate was 54% (15/28) and two patients progressed to epilepsy.
Conclusions: Patients with seizure have worse outcomes and longer hospitalization. Most first seizures occur within
one year after the diagnosis of HIV-negative cryptococcal meningitis.
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Despite advances in modern neurosurgical techniques,
new anti-fungal agents, and powerful imaging technolo-
gies, cryptococcal meningitis remains a potentially fatal
central nervous system (CNS) infection [1-3]. Seizures
are important neurologic complications that may occur
early or late in both HIV-negative and HIV-infected
cryptococcal meningitis [1-6]. The reported incidence var-
ies from 7.6% to 28.6% in different series [2,3]. To date,
only one clinical research has focused specifically on
seizures complicating HIV-negative cryptococcal men-
ingitis [3]. The indications and duration of seizure
treatment remain controversial [7], and the potential* Correspondence: chlu99@ms44.url.com.tw
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unless otherwise stated.adverse effects of anti-epileptic drugs (AEDs) are a con-
cern. Thus, treatment is mainly symptomatic.
The present hospital-based study may provide accur-
ate information on the relative frequency of seizure
sub-types and their effects on fatality and on neurologic
sequelae, and their relationship with underlying cere-
bral pathologic lesions. Because of the benefits of AEDs
in reducing morbidity after seizures, there is a need for
better delineation of potential prognostic factors and
outcomes in hospitalized patients with HIV-negative
cryptococcal meningitis who should receive treatment.
This study analyzed the clinical features, neuro-imaging
findings, clinical scores, and measurements to deter-
mine potential risk factors predictive of seizures in
HIV-negative cryptococcal meningitis.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Study population
The medical records of patients with HIV-negative crypto-
coccal meningitis admitted to Kaohsiung Chang Gung Me-
morial Hospital between 1986 and 2007 were reviewed for
blood cultures, microbiologic records, and neuro-imaging
findings using pre-existing standardized evaluation forms.
Kaohsiung Chang Gung Memorial Hospital is a 2482-bed
acute-care teaching hospital that provides both primary
and tertiary referral care.Diagnostic criteria of HIV-negative cryptococcal
meningitis
Patients with HIV-negative cryptococcal meningitis were
included if they had: (1) positive isolation of Cryptococcus
neoformans (C. neoformans) in one or more cerebro-
spinal fluid (CSF) cultures, positive CSF cryptococcal anti-
gen titer, or positive CSF India ink and clinical features of
meningitis; or (2) isolation of C. neoformans in blood cul-
ture, with clinical presentations of meningitis and typical
CSF features [1].
Patients were excluded if they had a history of seizures;
pre-existing neurologic conditions with various neurologic
deficits (e.g. stroke, head trauma, and hypoxic encephalop-
athy); or regularly took AEDs for epilepsy or other clinical
indications (e.g. trigeminal neuralgia or neuropathic pain).
Thus, only 180 of 185 patients were enrolled for analysis.Definition of seizures
Seizures were classified according to the recommenda-
tions of the International League against Epilepsy [8].
Status epilepticus (SE) was defined as a continuous be-
havioral seizure activity or repetitive seizures without full
recovery of neurologic function between seizures, lasting
longer than 30 minutes [9]. Seizure was defined accord-
ing to those used in previous studies [10-12]. Seizures
occurring after HIV-negative cryptococcal meningitis
were causally related to the HIV-negative cryptococcal
meningitis itself. A provoked (acute symptomatic) seiz-
ure was one that occurred in close temporal relation
with HIV-negative cryptococcal meningitis, which was
the presumed etiology [10-12]. In contrast, an unpro-
voked seizure was a seizure occurring in the absence of
one or more precipitating factors, including events in
patients with previously stable (non-progressing) HIV-
negative cryptococcal meningitis [10-12].
Epilepsy was the occurrence of repeated unprovoked
seizures [5,10-12]. Based on seizures onset in relation to
the clinical ictus of HIV-negative cryptococcal meningitis,
patients with seizures were divided into two sub-types.
Early seizures were those occurring within two weeks of
the infection, whereas late seizures were those occurring
after two weeks.Study protocol
All of the patients underwent brain computed tomog-
raphy (CT) scan at the emergency room. Follow-up brain
CT scans and/or magnetic resonance imaging (MRI) were
performed if there was clinical deterioration, including
acute onset focal neurologic deficits, seizures or status epi-
lepticus, progressively disturbed consciousness, and for
post-neurosurgical procedure. Hydrocephalus was judged
retrospectively by dilated temporal horn of the ventricle
without obvious brain atrophy and/or an Evan’s ratio >0.3
on initial CT scan. The Evan’s ratio was the ratio of the
ventricular width of the bilateral frontal horn to the max-
imum biparietal diameter [13,14].
The hospital’s standard protocol for HIV-negative
cryptococcal meningitis was to administer AEDs only
to those with acute symptomatic seizures. Prophylactic
AED therapy was not given to asymptomatic patients in
the acute stage. The AEDs were administered to pa-
tients with HIV-negative cryptococcal meningitis dur-
ing hospitalization and were discontinued if there were
no unprovoked seizures on follow-up.
The follow-up period was terminated by death or by the
end of the study (December 2007). Most patients were
followed-up at the out-patient department after discharge,
while others were interviewed by telephone to identify
neurologic outcomes. The frequency of seizures was deter-
mined by a Seizure Frequency Scoring System, which was
slightly modified from Engel et al. [15] and a previous study
[16]. Good outcome was defined as survival while poor out-
come was defined as fatality during the follow-up period.
The hospital’s Institutional Review Committee on Human
Research approved the study protocol.
Anti-fungal therapy
In the study hospital, anti-fungal therapy in patients with
HIV-negative cryptococcal meningitis was started accord-
ing to the preference of the attending physician [1,17-18].
The patients were divided into three major groups: Group
I received Amphotericin B intravenously, with or without
5-flucytosine, for 6–10 weeks, for a total intravenous dose
of 2–3 g; Group II received Amphotericin B with flucona-
zole 300–400 mg intravenously in the first 2–3 weeks, be-
fore treatment was switched to oral fluconazole alone
(300–400 mg daily for 10 weeks); and Group III, received
Fluconazole 400–800 mg intravenously daily during the
first 2 weeks and then switched to an oral dose of 300–
400 mg daily for the duration of primary therapy.
Statistical analysis
Two separate statistical analyses were performed. First, the
demographic data between the good and poor outcome
groups were compared. Categorical variables were com-
pared using the Chi-square test or Fischer’s exact test, as
appropriate. Continuous variables within two groups were
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and the Mann–Whitney U test for non-parametric data.
Second, to determine risk factors independently associated
with seizures or fatality, the clinical and laboratory parame-
ters with a p value <0.05 in univariate analysis were entered
in a logistic regression model using a stepwise entry sys-
tem. All statistical analyses were conducted using the SAS
software package, version 13.0 (2002, SAS Statistical Insti-
tute, Cary, North Carolina).
Results
Baseline data of the study patients
The 180 patients (age, 18–88 years) with HIV-negative
cryptococcal meningitis included 110 males and 70 fe-
males (mean age, 50.2 and 56.5 years, respectively).
Their characteristics in terms of seizures (Table 1) re-
vealed that 28 had seizures.
Neuro-imaging findings
The neuro-imaging findings of the HIV-negative crypto-
coccal meningitis patients with or without seizures were
listed in Table 2. Hydrocephalus, gyral enhancement,
basal cistern effacement, and cerebral infarction were
the four most common findings in the seizure group,
while hydrocephalus, dilated Virchow-Robin space, and
gyral enhancement were the three most common find-
ings in the non-seizure group.
Clinical characteristics and seizure outcomes
Regarding seizure onset in relation to the clinical ictus
of HIV-negative cryptococcal meningitis, 13 had earlyTable 1 Characteristics of patients with HIV-negative cryptoco
With seizures§
Early seizures
n = 13 (%)
Mean age, years 47.3 ± 17.3
Sex (male/female) 7/6




Disturbed consciousness 8 (61.5)
Visual disturbance 2 (15.3)




Mean length of hospitalization (days) 58.0 ± 38.9
Abbreviations: HIV, human immuno-deficiency virus; GCS, Glasgow Coma Scale; SD,
Categorical data is presented as %.
§Patients with early and late seizure were compared.seizures and 15 had late seizures (Table 1). The mean
time interval from HIV-negative cryptococcal meningitis
to first seizure in the early and late seizure groups were
1.5 and 51.4 days, respectively (Figure 1). Nine of the 28
cases (32%) occurred within 24 hours of presentation.
As regards seizure sub-types among the 28 cases, 18
were generalized tonic-clonic (64.3%, 18/28), 5 were
focal seizures with secondary generalized seizures
(17.8%, 5/28), three were myoclonic seizures (10.7%,
3/28), one was simple partial seizure (3.6%, 1/28), and
the remaining one was complex partial seizure (3.6%,
1/28). Three (10.7%, 3/28) of the 28 cases progressed
to status epilepticus.
In terms of treatment, 22 were treated with phenytoin
alone, three with valproic acid alone, and the remaining
three with both valproic acid and phenytoin. The mean
duration of AED therapy for those who were discharged
on AEDs was 12.9 ± 7.3 months. None of the 28 pa-
tients had drug-related complications.
The mean duration of hospitalization for the seizure
and non-seizure groups was 77.54 ± 56.14 and 56.9 ±
5.29 days, respectively (p = 0.05). Fifteen (53.6%, 15/28)
died in the acute phase of HIV-negative cryptococcal
meningitis, while 13 (46.4%, 13/28) survived. In terms of
seizure control after discharge among the 13 survivors, 5
(38.4%, 5/13) were seizure-free without AED therapy, 6
(46.2%, 6/13) were seizure-free under AED therapy, one
(7.7%, 1/13) had 4–11 seizures per year, and the remaining
one (7.7%, 1/13) had 1–3 seizures per month.
Twenty-three (12.8%, 23/180) cases were lost to follow-
up after discharge during the study period. In total, 123 ofccal meningitis in terms of seizures (n = 180)
Without
seizuresLate seizures p value
n = 15 (%) n = 152 (%)
52.1 ± 25.0 0.32 53.2 ± 17.9
9/6 0.74 92/60
12.1 ± 4.4 0.71 13.1 ± 3.1
13 (86.6) 0.20 89 (58.5)
9 (60) 0.71 69 (45.3)
8 (53.3) 0.66 61 (40.1)
5(33.3) 0.61 26 (17.1)
1 (6.6) 1.0 4 (2.6)
2 (13.3) 0.64 21 (13.8)
10 (66.6) 0.14 42 (27.6)
89.3 ± 62.6 0.08 56.9 ± 49.3
standard deviation; IQR, inter-quartile range.
Table 2 Neuro-imaging findings
Seizures after cryptococcal meningitis§ Without seizures
Early seizures Late seizures p value
n = 13 (%) n = 15 (%) n = 152 (%)
Hydrocephalus 7 (53.8) 6 (40.0) 0.743 51 (33.5)
Dilated Virchow-Robin space 1 (7.6) 1 (6.6) 1.0 13 (8.5)
Gyral enhancement 3 (23.0) 2 (13.3) 1.0 12 (7.8)
Basal cistern effacement 1 (7.7) 3 (20.0) 0.464 11 (7.2)
Pseudo-cyst 0 0 1.0 11 (7.2)
Cerebral infarction 0 4 (26.7) 0.644 10 (6.5)
Mass lesions 0 2 (13.3) 1.0 10 (6.5)
§Categorical data of neuroimaging findings between early seizure and late seizure were compared using Chi-square test or Fischer’s exact test.
Categorical data is presented as %.
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the seizure and non-seizure groups was 54% (15/28) and
12% (42/152), respectively. The mean age at onset, median
days of hospitalization, and median GCS on admission be-
tween the two groups were listed in Table 3.
Risk factors and outcome of epilepsy and fatality
Comparisons of clinical features and neuro-imaging find-
ings between the seizure and non-seizure groups were
listed in Table 3. Statistical analysis between the two patient
groups revealed that only thrombocytopenia (p = 0.028)
and neuro-imaging findings at presentation showing
gyral enhancement (P = 0.042) were significant vari-
ables. After stepwise logistic regression analysis, both
thrombocytopenia (p = 0.035, 95% CI: 1.09-9.76) and
neuro-imaging findings at presentation showing gyral
enhancement (p = 0.048, 95% CI 1.01-8.873) were inde-
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Figure 1 The frequency distribution of patients with first seizures afte
period (months).Comparisons of clinical features and neuro-imaging
findings between survivors and non-survivors after a
minimum of 5 years of follow-up were listed in Table 4.
Statistical analysis between the two groups revealed that
mean GCS on admission (p < 0.001), presence of under-
lying diseases as liver cirrhosis (p = 0.004) and iatrogenic
Cushing syndrome (p = 0.016), and the presence of sei-
zures (p = 0.007) and CSF cryptococcal antigen titer
≥1:1024 and lactate level (p = 0.015) were all significant
variables. Significant univariate factors used in the step-
wise logistic regression were mean GCS on admission,
presence of underlying diseases (liver cirrhosis and iatro-
genic Cushing syndrome), seizures, and CSF crypto-
coccal antigen titer (≥1:1024 or not) and lactate level.
After analysis, only mean GCS on admission (OR:
0.835, 95% CI, 0.737-0.946; p = 0.005), presence of acute
seizures (OR: 3.683, 95% CI: 1.332-10.18; p = 0.012),
presence of underlying diseases such as liver cirrhosis2~24 24~36 36~60 60~120 120~252
gative cryptococcal meningitis during follow-up
 (months)
izure
r HIV-negative cryptococcal meningitis during the study
Table 3 Comparison of baseline clinical features and neuro-imaging findings between HIV-negative cryptococcal
meningitis patients with and those without seizures
Without seizures n = 152 (%) With seizures n = 28 (%) p value OR 95% CI
Sex (Male/female) 92/58 16/12 0.76
Mean age at onset 53.18 ± 17.86 49.86 ± 21.48 0.446
Mean GCS on presentation 13.05 ± 3.11 11.79 ± 4.10 0.064
Underlying diseases
Diabetes mellitus 27 (17.8) 7 (25.0) 0.369 1.543 0.596-3.995
Pulmonary TB 8 (5.3) 4 (14.2) 0.095 3 0.838-10.743
Systemic lupus erythematosus 7 (4.6) 1 (3.6) 1 0.767 0.091-6.489
Liver cirrhosis 9 (5.9) 4 (14.3) 0.123 2.648 0.755-9.286
Chronic alcoholism 3 (2.0) 0 1 0.842 0.79-0.897
Autoimmune diseases 4 (2.6) 1 (3.6) 0.575 1.37 0.147-12.736
Hematological diseases 7 (4.6) 1 (3.6) 1 0.767 0.091-6.489
Malignance 10 (6.6) 1 (3.6) 1 0.526 0.065-4.279
Iatrogenic Cushing syndrome 12 (7.9) 1 (3.6) 0.695 0.432 0.054-3.463
Clinical features
Fever/chills 89 (58.6) 21 (75.0) 0.101 2.124 0.851-5.298
Headache 69 (45.4) 18 (64.3) 0.066 2.165 0.938-4.997
Disturbed consciousness 61 (40.1) 16 (57.1) 0.095 1.989 0.88-4.497
Visual disturbance 19 (12.5) 7 (25.0) 0.084 2.333 0.875-6.225
Hearing impairment 4 (2.6) 2 (7.1) 0.235 2.846 0.496-16.342
Neuro-imaging findings at presentation
Hydrocephalus 74 (48.7) 16 (57.1) 0.411 1.405 0.623-3.170
Cerebral infarction 14 (9.2) 4 (14.2) 0.489 1.643 0.498-5.415
Gyral enhancement 13 (8.6) 6 (21.4) 0.042 2.916 1.003-8.474
Basal cistern effacement 10 (6.6) 1 (3.6) 1 0.526 0.065-4.279
Pseudo-cyst 7 (4.6) 4 (14.2) 0.071 3.452 0.939-12.696
Dilated Virchow-Robin space 10 (6.6) 3 (10.7) 0.43 1.704 0.438-6.629
Mass lesions 8 (5.3) 2 (7.1) 0.656 1.385 0.278-6.891
Peripheral blood testing
Leukocytosis 35 (23.0) 10 (35.7) 0.154 1.857 0.786-4.390
Leucopenia 2 (1.3) 0 1 0.843 0.791-0.898
Thrombocytopenia 12 (7.9) 6 (21.4) 0.028 3.182 1.083-9.352
Hyponatremia 21 (13.8) 5 (17.8) 0.576 1.356 0.465-3.958
CSF study
Opening pressure (mmH2O) 305 ± 80.9 387.3 ± 154.1 0.09
Sugar (mg/dl) 39.04 41.16 0.766
Total Protein (mg/dl) 203.78 285.95 0.282
Lactate (mg/dl) 51.56 61.67 0.217
CSF cryptococcal antigen titer
≥1:1024 73 (48.0) 16 (57.1) 0.375 1.44 0.64-3.25
<1:1024 79 (52.0) 12 (42.9)
Outcome
Median (IRQ) hospitalization days 56.9 ± 45.29 77.54 ± 56.14 0.050
Abbreviation: HIV human immuno-deficiency virus.
Categorical data is presented as %.
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Table 4 Risk factors for fatality in HIV-negative cryptococcal meningitis
Non-fatality n = 123 (%) Fatality n = 57 (%) p value OR 95% CI
Sex (Male/female) 76/45 32/25 0.435
Mean age at onset 50.89 ± 18.8 56.49 ± 17.16 0.058
Mean GCS on presentation 13.65 ± 12.35 11.12 ± 4.30 <0.0001
Underlying diseases
Diabetes mellitus 20 (16.2) 14 (24.6) 0.186 1.677 0.776-3.622
Pulmonary TB 8 (6.5) 4 (7.0) 1 1.085 0.313-3.762
Systemic lupus erythematosus 7 (5.7) 1 (1.8) 0.439 0.296 0.036-2.464
Liver cirrhosis 4 (3.3) 9 (15.8) 0.004 5.578 1.639-18.98
Chronic alcoholism 1 (0.8) 2 (3.5) 0.236 4.436 0.394-49.964
Autoimmune diseases 2 (1.6) 3 (5.2) 0.328 3.361 0.546-20.697
Hematologic diseases 6 (4.9) 2 (3.5) 1 0.709 0.139-3.627
Malignance 6 (4.9) 5 (8.8) 0.31 1.875 0.548-6.421
Iatrogenic Cushing syndrome 5 (4.0) 8 (14.0) 0.016 3.853 1.201-12.364
Clinical features
Fever/chills 68 (55.3) 42 (73.7) 0.018 2.265 1.138-4.508
Headache 60 (48.8) 27 (47.4) 0.86 0.945 0.504-1.772
Disturbed consciousness 44 (35.8) 33 (57.9) 0.005 2.469 1.299-4.692
Visual disturbance 19 (15.4) 7 (12.3) 0.574 0.766 0.302-1.942
Hearing impairment 4 (3.3) 2 (3.5) 1 1.082 0.192-6.085
Seizure 13 (10.6) 15 (26.3) 0.007 3.022 1.326-6.885
Neuro-imaging findings at presentation
Hydrocephalus 59 (48.0) 31 (54.4) 0.423 1.293 0.689-2.428
Cerebral infarction 12 (9.8) 6 (10.5) 0.873 1.088 0.387-3.062
Gyral enhancement 13 (10.6) 6 (10.5) 0.996 0.995 0.358-2.768
Basal cistern effacement 5 (4.0) 6 (10.5) 0.092 2.776 0.81-9.513
Pseudo-cyst 8 (6.5) 3 (5.3) 1 0.799 0.204-3.129
Dilated Virchow-Robin space 9 (7.3) 4 (7.0) 1 0.956 0.282-3.245
Mass lesions 6 (4.9) 4 (7.0) 0.728 1.472 0.399-5.433
Peripheral blood testing
Leukocytosis 28 (22.8) 17 (29.8) 0.309 1.442 0.711-2.924
Leucopenia 2 (1.6) 0 1 0.68 0.615-0.752
Thrombocytopenia 9 (7.3) 9 (15.8) 0.078 2.375 0.888-6.351
Hyponatremia 17 (13.8) 9 (15.8) 0.727 1.169 0.486-2.81
CSF study
Opening pressure (mmH2O) 356.7 ± 143.6 379.9 ± 149.3 0.679
Sugar (mg/dl) 40.77 ± 34.11 35.69 ± 27.80 0.390
Total Protein (mg/dl) 210.30 ± 360.94 235.75 ± 339.47 0.688
Lactate (mg/dl) 48.76 ± 34.90 65.38 ± 40.92 0.015
CSF cryptococcal antigen titer
≥1:1024 48 (39.0) 41 (71.9) <0.001 4.0 2.03-7.92
<1:1024 75 (61.0) 16 (28.1)
Outcome
Median (IRQ) hospitalization days 63.32 ± 49.39 48.44 ± 38.43 0.107
Abbreviation: HIV human immuno-deficiency virus.
Categorical data is presented as %.
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Cushing syndrome (OR: 4.574, 95% CI: 1.185-17.66; p =
0.027) and CSF cryptococcal antigen titer ≥1:1024 (OR:
3.614, 95% CI: 1.093-6.247; p = 0.031) were independ-
ently associated with fatality. Any reduction of one point
of GCS increased the fatality rate by 17%.
Discussion
The frequency of seizures after HIV-negative cryptococcal
meningitis is variously estimated at 7.6-28.6% [2,3]. To
date, this is the largest study to show long-term outcomes
of seizures among patients with HIV-negative crypto-
coccal meningitis. In this study, seizures occur in 28 out
of 180 patients (15.6%), including early seizures in 13
(7.2%) and late seizures in 15 (8.3%). Among the 28 with
seizure, two progressed to epilepsy.
Major findings
The present study examined the predictive factors and
outcomes of seizures in patients with HIV-negative
cryptococcal meningitis and produced two major findings.
First, patients with seizure had longer mean length of
hospitalization. Lower mean GCS on admission and the
presence of seizures were independently associated with
fatality, and any reduction of one point of GCS increased
the fatality rate by 17%. Second, seizures in patients with
HIV-negative cryptococcal meningitis might have delayed
manifestations although most seizures occur during the
acute phase of the meningitis. None of the patients had a
first seizure occurring more than one year after the diag-
nosis of HIV-negative cryptococcal meningitis. The occur-
rence of seizures was commonly observed within 24 hours
of presentation in one study [3], as well as in the present
study, and accounted for 100% (8/8) and 32% (9/28) of
cases, respectively.
The use of prophylactic AED therapy for preventing sei-
zures in patients with HIV-negative cryptococcal meningi-
tis remains unclear. A possible benefit is the reduction in
morbidity after seizures. At present, no formal recommen-
dations can be made regarding the use of prophylactic
AEDs for patients with HIV-negative cryptococcal menin-
gitis based on currently available well-designed random-
ized controlled trials. Phenytoin is the most widely used
AED in this study and there are no observed adverse ef-
fects related to its use.
In this study, lower mean GCS on admission, presence
of acute seizures, presence of underlying diseases like liver
cirrhosis and iatrogenic Cushing syndrome, and CSF
cryptococcal antigen titer ≥1:1024 are independently asso-
ciated with fatality. The CSF cryptococcal-antigen titer
>1:1024 may imply severe infection. It is also a significant
prognostic factor in both HIV-negative and HIV-positive
cryptococcal meningitis [1,19]. There is a striking correl-
ation between initial consciousness level and therapeuticoutcome, and this is consistent with findings of other re-
ports [20,21]. The presence of underlying diseases such as
liver cirrhosis and iatrogenic Cushing syndrome is also a
well-known predisposing factor of poor outcome [22,23].
Seizures complicating HIV-negative Cryptococcal men-
ingitis have worse outcomes and longer hospitalization.
There may be several reasons for the increased mortality
and morbidity in patients with seizures. For instance, pa-
tients are commonly associated with underlying medical
conditions. Moreover, later neurologic morbidity is attrib-
utable to hypoxia, lactic acidosis, increased intra-cranial
pressure (IICP), and autonomic dysfunction.
Study limitations
First, this was a retrospective analysis and therefore subject
to bias of unmeasured factors (e.g. possible reporting bias
due to patient selection presented to the hospital). It was
also not possible to assess the effects of prophylactic AEDs
after the acute stage of HIV-negative cryptococcal menin-
gitis. Second, patients who took AEDs for epilepsy or other
clinical indications (e.g. trigeminal neuralgia or neuropathic
pain) or those with pre-existing neurologic deficits were
excluded. Thus, there was continued uncertainty in asses-
sing the incidence of unprovoked seizures after HIV-
negative cryptococcal meningitis in non-selected patients.
Third, the impact of surgical intervention for hydroceph-
alus on the frequency of seizures was not clear. Surgical in-
terventions might cause potential brain insults and lead to
unprovoked seizures during follow-up. Lastly, most pa-
tients in this study were treated with AEDs after their first
acute symptomatic seizure, in accordance with the study
protocol. Thus, the findings might underestimate the “true”
frequency of seizures associated with the “natural history”
of untreated unprovoked seizures.
Conclusions
Among patients with HIV-negative cryptococcal menin-
gitis, those with seizure have worse outcome and longer
hospitalization. Most first seizures occur within one year
of diagnosis of meningitis. Thus, prophylactic treatment,
if considered, should not be performed for a period of
more than one year.
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